WO1999042465A3 - Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation - Google Patents

Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation Download PDF

Info

Publication number
WO1999042465A3
WO1999042465A3 PCT/EP1999/001013 EP9901013W WO9942465A3 WO 1999042465 A3 WO1999042465 A3 WO 1999042465A3 EP 9901013 W EP9901013 W EP 9901013W WO 9942465 A3 WO9942465 A3 WO 9942465A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
group
heterocyclic ring
hydrogen
optionally substituted
Prior art date
Application number
PCT/EP1999/001013
Other languages
French (fr)
Other versions
WO1999042465A2 (en
Inventor
Steven Mark Bromidge
Halina Teresa Serafinowska
Original Assignee
Smithkline Beecham Plc
Steven Mark Bromidge
Halina Teresa Serafinowska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Steven Mark Bromidge, Halina Teresa Serafinowska filed Critical Smithkline Beecham Plc
Priority to JP2000532417A priority Critical patent/JP2002504484A/en
Priority to EP99910228A priority patent/EP1066288A2/en
Priority to CA002321278A priority patent/CA2321278A1/en
Publication of WO1999042465A2 publication Critical patent/WO1999042465A2/en
Publication of WO1999042465A3 publication Critical patent/WO1999042465A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Novel sulphonamide derivatives of formula (I) or a salt thereof having CNS activity, processes for their preparation and their use as medicaments: in which E is -SO2NH- or -NHSO2- P is a phenyl, naphthyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur; A is a single bond, a C1-6alkylene or a C1-6alkenylene group; R1 is halogen, C¿1-6?alkyl optionally substituted by one or more fluorine atoms, C3-6cycloalkyl, C1-6alkoxy, OCF3, C1-6alkoxyC1-6alkoxy; C1-6alkanoyl, amino, alkylamino or dialkylamino, SR?11¿ where R11 is hydrogen or C¿1-6?alkyl or R?1¿ is phenyl, benzyl, naphthyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur; and n is 0, 1, 2, 3, 4 or 5; R3 is a group R5 or together with R5 forms a group (CH¿2?)2O or (CH2)3O; R?4¿ is selected from a group of formula (i), (ii) or (iii): Formula (i) in which R6 is C¿1-6?alkyl optionally substituted by one or more halogen atoms; m is 0, 1 or 2; q is 0, 1, 2, 3 or 4; or Formula (ii) in which R?6¿, m and q are as defined in formula (i); or Formula (iii) in which R6, and q are as defined in formula (I) and R7 is hydrogen or C¿1-6?alkyl; R?5¿ is hydrogen, halogen, C¿1-6?alkoxy optionally substituted with one or more fluorine atoms, trifluoromethyl, or together with R?3¿ forms a group (CH¿2?)2O or (CH2)3O.
PCT/EP1999/001013 1998-02-18 1999-02-12 Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation WO1999042465A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000532417A JP2002504484A (en) 1998-02-18 1999-02-12 New compound
EP99910228A EP1066288A2 (en) 1998-02-18 1999-02-12 Novel compounds
CA002321278A CA2321278A1 (en) 1998-02-18 1999-02-12 Novel compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9803411.9 1998-02-18
GBGB9803411.9A GB9803411D0 (en) 1998-02-18 1998-02-18 Novel compounds

Publications (2)

Publication Number Publication Date
WO1999042465A2 WO1999042465A2 (en) 1999-08-26
WO1999042465A3 true WO1999042465A3 (en) 1999-09-30

Family

ID=10827185

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/001013 WO1999042465A2 (en) 1998-02-18 1999-02-12 Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation

Country Status (5)

Country Link
EP (1) EP1066288A2 (en)
JP (1) JP2002504484A (en)
CA (1) CA2321278A1 (en)
GB (1) GB9803411D0 (en)
WO (1) WO1999042465A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9926303D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
US6586592B2 (en) 2000-06-20 2003-07-01 Pharmacia & Upjohn Company Bis-arylsulfones
PE20020063A1 (en) 2000-06-20 2002-01-30 Upjohn Co BIS-ARYLSULFONES AS LIGANDS OF THE 5-HT RECEPTOR
SE0002754D0 (en) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
US6399617B1 (en) 2000-07-21 2002-06-04 Biovitrum Ab Use
SE0002739D0 (en) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New use
GB0021450D0 (en) * 2000-08-31 2000-10-18 Smithkline Beecham Plc Novel compounds
CA2422807C (en) * 2000-09-18 2009-12-08 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
US7071220B2 (en) 2000-09-18 2006-07-04 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
US7718650B2 (en) 2001-05-11 2010-05-18 Biovitrum Ab Aryl sulfonamide compounds for treating obesity
AU2002303061B2 (en) * 2001-05-11 2009-01-29 Biovitrum Ab (Publ) Novel, arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders
JP4731114B2 (en) 2001-06-11 2011-07-20 プロキシマゲン・リミテッド Substituted sulfonamide compounds, methods for their use as medicaments for the treatment of CNS disorders, obesity and type II diabetes
KR100608417B1 (en) 2001-08-10 2006-08-02 에프. 호프만-라 로슈 아게 Arylsulfonyl derivatives with 5-ht6 receptor affinity
WO2003039547A1 (en) * 2001-11-09 2003-05-15 Biovitrum Ab Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake
ES2260607T3 (en) * 2002-02-13 2006-11-01 Glaxo Group Limited DERIVATIVES OF 7-ARILSULFONAMIDO-2,3,4,5-TETRAHIDRO-1H-BENZO-DIAZEPINA AFFINISHED BY 5-HT6 RECEPTORS FOR THE TREATMENT OF CNS DISORDERS.
BR0307557A (en) * 2002-02-13 2005-01-04 Glaxo Group Ltd Benzenesulfonamide derivatives as antipsychotic agents
AU2003218660A1 (en) * 2002-02-13 2003-09-04 Glaxo Group Limited Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor liga ds
WO2003078419A1 (en) * 2002-03-15 2003-09-25 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivative
BRPI0308696B8 (en) 2002-03-27 2021-05-25 Axovant Sciences Gmbh quinoline-derived compound, its preparation process, its pharmaceutical composition and its uses
MXPA04011465A (en) 2002-05-24 2005-02-14 Millennium Pharm Inc Ccr9 inhibitors and methods of use thereof.
EP1897881A3 (en) 2002-06-20 2009-03-18 Biovitrum AB (publ) Compounds useful for the treatment of obesity, type II diabetes and CNS disorders
US7943639B2 (en) 2002-06-20 2011-05-17 Proximagen Limited Compounds
JP2006504690A (en) * 2002-09-10 2006-02-09 ファイザー・プロダクツ・インク Diazabicyclic compounds useful for the treatment of CNS and other disorders
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
DK1562940T3 (en) 2002-11-18 2007-10-01 Chemocentryx Inc arylsulfonamides
WO2005012254A1 (en) 2003-07-22 2005-02-10 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related therto
SE0303480D0 (en) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
FR2865208B1 (en) * 2004-01-16 2009-01-16 Sanofi Synthelabo 1,4-DIAZABICYCLO [3.2.1] OCTANECARBOXMIQUE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
BRPI0506890A (en) 2004-02-04 2007-07-17 Neurosearch As diazabicyclically arila derivative, pharmaceutical composition, use of a diazabicyclically arila derivative, and, method of treatment, prevention or alleviation of a disease, disorder or condition of a living animal body
CA2575359A1 (en) 2004-07-28 2006-02-02 Glaxo Group Limited Piperazine derivatives useful for the treatment of gastrointestinal disorders
EP1676841A1 (en) * 2004-12-30 2006-07-05 Esteve Laboratorios Dr. Esteve S.A. Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments
DE602006019561D1 (en) 2005-02-16 2011-02-24 Neurosearch As DIAZABICYCLIC ARYL DERIVATIVES AND THEIR USE AS CHINOLINERGIC LIGANDS ON NICOTIN ACETYLCHOLINE RECEPTORS
ATE481407T1 (en) 2005-02-16 2010-10-15 Neurosearch As NEW DIAZABICYCLIC ARYL DERIVATIVES AND MEDICAL USE THEREOF
MX2008002018A (en) 2005-08-12 2008-03-27 Suven Life Sciences Ltd Aminoaryl sulphonamide derivatives as functional 5-ht6 ligands.
US7923566B2 (en) 2005-08-16 2011-04-12 Suven Life Sciences Limited Alternative process for the preparation of losartan
JP2009531385A (en) 2006-03-31 2009-09-03 グラクソ グループ リミテッド Piperazine derivatives as growth hormone secretagogue (GHS) receptor agonists
ATE491685T1 (en) 2007-01-08 2011-01-15 Suven Life Sciences Ltd 5-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS
DK2155674T3 (en) 2007-05-03 2011-09-26 Suven Life Sciences Ltd Aminoalkoxy-aryl-sulfonamide compounds and their use as 5-HT6 ligands
ES2574154T3 (en) * 2007-08-07 2016-06-15 Abbvie Deutschland Gmbh & Co Kg Quinoline compounds suitable for treating disorders that respond to serotonin 5-HT6 receptor modulation
BRPI0816571A2 (en) 2007-10-26 2015-12-22 Suven Life Sciences Ltd "compound, process for preparing the compound, pharmaceutical composition, agent and method for treating a disease or disorder of the central nervous system related to or affected by the 5-ht6 receptor"
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
EP2103596A1 (en) 2008-03-18 2009-09-23 Laboratorios Del. Dr. Esteve, S.A. Process for the preparation of N-(phenylethyl) anilines salts and solvates thereof useful as serotonin 5-HT6 antagonists
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
MX2011002884A (en) 2008-09-17 2011-04-21 Suven Life Sciences Ltd Aryl sulfonamide amine compounds and their use as 5-ht6 ligands.
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
JP5628937B2 (en) 2010-01-05 2014-11-19 スベン ライフ サイエンシズ リミティド Sulfone compounds as 5-HT6 receptor ligands
MX2017016413A (en) 2015-06-12 2018-08-01 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder.
MX2018000465A (en) 2015-07-15 2018-09-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0815861A1 (en) * 1996-06-28 1998-01-07 F. Hoffmann-La Roche Ag Sulphonamides and their use
WO1998027081A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Sulphonamide derivatives, process for their preparation, and their use as medicaments
WO1998027058A2 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc N-piperazin-1-ylphenyl-benzamide derivatives
WO1999002502A2 (en) * 1997-07-11 1999-01-21 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0815861A1 (en) * 1996-06-28 1998-01-07 F. Hoffmann-La Roche Ag Sulphonamides and their use
WO1998027081A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Sulphonamide derivatives, process for their preparation, and their use as medicaments
WO1998027058A2 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc N-piperazin-1-ylphenyl-benzamide derivatives
WO1999002502A2 (en) * 1997-07-11 1999-01-21 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BROMIDGE,S.M. ET AL.: "5-Chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide(SB-271046): A Potent, Selective, and Orally Bioavailable5-HT6 Receptor Antagonist", J.MED.CHEM., vol. 42, no. 2, 28 January 1999 (1999-01-28), WASHINGTON, pages 202 - 205, XP002109186 *
HOYER D AND MARTIN G: "5-HT receptor classification and nomenclature: towards a harmonization with the human genome", NEUROPHARMACOLOGY, no. 36, 1 April 1997 (1997-04-01), pages 419 428, XP002075372 *
MONSMA ET AL: "Cloning and Expression of A Novel Serotonin Receptor with High Affinity for Tricyclic Psychotropic Drugs", MOLECULAR PHARMACOLOGY, vol. 43, no. 3, 1 January 1993 (1993-01-01), pages 320 - 327, XP002093842 *
SAUDOU F ET AL: "5-HT RECEPTOR SUBTYPES: MOLECULAR AND FUNCTIONAL DIVERSITY", MEDICINAL CHEMISTRY RESEARCH, vol. 4, no. 1, 1 January 1994 (1994-01-01), pages 16 - 84, XP000604196 *
SLEIGHT ET AL: "The 5-hydroxytryptamine-6 receptor: localisation and function", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 8, no. 10, 1 October 1998 (1998-10-01), pages 1217 - 1224, XP002093843 *

Also Published As

Publication number Publication date
EP1066288A2 (en) 2001-01-10
JP2002504484A (en) 2002-02-12
CA2321278A1 (en) 1999-08-26
WO1999042465A2 (en) 1999-08-26
GB9803411D0 (en) 1998-04-15

Similar Documents

Publication Publication Date Title
WO1999042465A3 (en) Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
DE69716424T2 (en) PHENYL DERIVATIVES CONTAINING ACID GROUPS, THEIR PRODUCTION AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS
EA199800664A1 (en) SUBSTITUTED DERIVATIVES OF 4-HYDROXY-PHENYLALCANIC ACID WITH AGONISTIC ACTIVITY WITH RESPECT TO PPAR-GAMMA
WO1998050346A3 (en) Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
AR010795A1 (en) SULFONAMID-DERIVED COMPOUNDS, PROCEDURE FOR THE PREPARATION AND A PHARMACEUTICAL COMPOSITION
IL107869A0 (en) Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them
NZ503912A (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds and their use as substance P antagonists
DE69401716T2 (en) IMIDAZO [1,2-A] PYRASIN-4-ON DERIVATIVES, WHICH SERVE AS AMPA AND NMDA RECEPTOR ANTAGONISTS
DK0759027T3 (en) Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase
ES8307244A1 (en) Azobicycloalkylbenzamides, process for their preparation and pharmaceutical compositions containing them.
ES546377A0 (en) A PROCEDURE FOR THE PREPARATION OF TRICYCLIC OXINDAL-CARBOXAMIDES.
ES8300762A1 (en) Azabicycloalkane derivatives, their preparation and use.
WO2000005224A3 (en) Heterocyclic derivatives and their use as integrin inhibitor
AP9801410A0 (en) Indoline derivatives useful as 5-HT-2C receptor antagonists.
ATE48999T1 (en) PIPERAZINE-1-YL-ERGOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AU4455397A (en) Disubstituted morpholine, oxazepine or thiazepine derivatives, their preparation and their use as dopamine d4 receptor antagonists
DE3769333D1 (en) ACYLAMINOMETHYLIMIDAZO (1,2-A) PYRIMIDINE DERIVATIVES, THEIR PRODUCTION AND THERAPEUTIC USE.
ATE58135T1 (en) 1,3-OXATHIAN DERIVATIVES.
DE3479499D1 (en) Triazolo (2,3-c)(1,3)benzodiazepines, process for their preparation, pharmaceutical compositions containing them and their therapeutical use
DE69903930D1 (en) N-ARYLOXYETHYL-INDOLYL-ALKYLAMINE FOR TREATING DEPRESSIONS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999910228

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2321278

Country of ref document: CA

Ref country code: CA

Ref document number: 2321278

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09622453

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999910228

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999910228

Country of ref document: EP